Soligenix, Inc.
(NASDAQ : SNGX)

( )
SNGX After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Do You Like Swing Trading?
Learn how we win with easy 3-5 day holds.
Be 'active' in the market while NOT being tied to your desk.
100% secure: your email is never shared, and you may opt out at any time.
Loading SNGX News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
0.96%73.420.9%$713.07m
AMGNAmgen Inc.
0.08%179.321.1%$583.83m
CELGCelgene Corporation
0.97%136.311.1%$571.96m
REGNRegeneron Pharmaceuticals, Inc.
2.83%521.132.7%$511.51m
VRTXVertex Pharmaceuticals Incorporated
-0.23%159.331.9%$392.76m
BIIBBiogen Inc.
-0.18%281.441.2%$388.90m
ALXNAlexion Pharmaceuticals, Inc.
1.97%129.811.9%$272.80m
TSROTESARO, Inc.
4.02%129.0114.7%$168.19m
INCYIncyte Corporation
2.56%133.792.6%$164.97m
ILMNIllumina, Inc.
-1.10%171.973.5%$156.83m
EXELExelixis, Inc.
0.90%26.996.5%$154.24m
CLVSClovis Oncology, Inc.
1.69%85.2718.0%$152.78m
BMRNBioMarin Pharmaceutical Inc.
0.59%87.744.4%$131.34m
KITEKite Pharma, Inc.
4.23%109.8916.1%$121.79m
BLUEBluebird Bio, Inc.
-1.54%95.8019.3%$109.71m

Company Profile

Soligenix, Inc. is a clinical stage biopharmaceutical company, which engages in developing products to treat serious gastrointestinal diseases. It operates through the BioTherapeutics and Vaccines or BioDefense segments. The BioTherapeutics segment involves in the development of photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible light for the treatment of cutaneous T-cell lymphoma. The Vaccines or BioDefense segment includes active development programs for RiVax, ricin toxin vaccine candidate, OrbeShield, GI acute radiation syndrome therapeutic candidate, and SGX943, melioidosis therapeutic candidate. The company was founded in 1987 and is headquartered Princeton, NJ.